Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.56 |
| ▸ | CTSK | P43235 | 7/20 | 0.56 |
| ▸ | CTSL | P07711 | 2/20 | 0.55 |
| ▸ | CTSB | P07858 | 2/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | BCL2 | P10415 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2516660 | 1.00 | CTSS (0.56) | CTSSCTSKCTSLCTSBPPARG | |
| SCHEMBL2516655 | 1.00 | CTSS (0.56) | CTSSCTSKCTSLCTSBPPARG | |
| SCHEMBL20415725 | 0.88 | CTSS (0.57) | CTSSCTSKCTSLCTSBHDAC8 | |
| SCHEMBL31633736 | 0.88 | CTSS (0.70) | CTSSCTSKCTSLCTSBHDAC8 | |
| SCHEMBL13211222 | 0.87 | CTSS (0.71) | CTSSCTSKCTSLCTSBSCN9A | |
| SCHEMBL3004474 | 0.87 | CTSS (0.71) | CTSSCTSKCTSLCTSBHDAC8 | |
| SCHEMBL5556757 | 0.87 | CTSS (0.71) | CTSSCTSKCTSLCTSBHDAC8 | |
| SCHEMBL18607925 | 0.87 | PPARG (0.55) | CTSSCTSKCTSLCTSBPPARG | |
| SCHEMBL18262787 | 0.87 | PPARG (0.55) | CTSSCTSKCTSLCTSBPPARG | |
| SCHEMBL3004471 | 0.87 | CTSS (0.71) | CTSSCTSKCTSLCTSBHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858314-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2020-12-08 | — | — | US | disclosed |
| US-20180208552-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858314-B2 | Urea derivative or pharmacologically acceptable salt thereof | FPR1, SAAL1, FPR2 | CTSS 1485/4885CTSK 2965/4885CTSL 157/4885 |
| US-20180208552-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | FPR1, FPR2, SAAL1 | CTSS 1488/4885CTSK 2892/4885CTSL 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.